title: Discussion: Managing Risk When Using Idelalisib.
authors.affiliation: Stanford University Medical Center, Stanford, California.
authors.forename: Steven E
authors.initials: SE
authors.lastname: Coutre
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Jan A
authors.initials: JA
authors.lastname: Burger
authors.affiliation: Hematopoietic Stem Cell Transplantation Program, Swedish Cancer Institute, Seattle, Washington.
authors.forename: John M
authors.initials: JM
authors.lastname: Pagel
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003092:Colitis / Q000209:etiology; D019468:Disease Management; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D006801:Humans; D011687:Purines / Q000009:adverse effects* / Q000627:therapeutic use; D052999:Quinazolinones / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment
chemical_list: D000970:Antineoplastic Agents; D011687:Purines; D052999:Quinazolinones; C552946:idelalisib